INDIAN-IMMIGRATION
8.6.2022 10:02:10 CEST | Business Wire | Press release
India has recently become a popular tourist destination for travelers thanks to the breathtaking sceneries it has to offer. Besides adventure travel and cultural tours, wellness tourism in India has emerged as a significant and rapidly expanding tourism segment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220608005070/en/
The growth of wellness tourism in India
In 2020, India ranked 12th in the top 20 largest wellness tourism markets in the world, with more than 48.2 million wellness trips. Making use of this travelers' interest, India offers plenty of wellness retreats and resorts for tourists as well as advantageous conditions to get Indian visas.
Many travelers may be confused about the difference between wellness tourism and medical tourism . Medical tourism is about traveling to a different place for specific medical treatments while wellness tourism is associated with the pursuit of maintaining or enhancing travelers’ wellbeing.
Especially, more people are choosing health and wellness tourism in India to recharge their batteries and refresh themselves post pandemic.
Lauren Jane, an American traveler who had a wellness vacation in Ananda in the Himalayas Resort, India, says: “The activities here help me re-balance and relieve stress after the pandemic, while the healthy organic cuisine maintains my health during the trip. I will come back to experience more wellness tourism destinations in India.”
Typical types of wellness tourism in India and corresponding entry documents
India focuses on promoting wellness tourism in 03 key sectors: Meditation, yoga, and massage therapies.
One of the most popular activities on a wellness trip in India is meditation. Travelers will participate in meditation activities in a natural space of plants, water, and clouds. Meditation is a good way for tourists to reset their bodies, and enjoy the moments of relaxation in their souls.
Known as the birthplace of yoga, India promotes the construction of wellness retreats suitable for yoga practices. Most of the retreats are settled close to nature, surrounded by the lush green forests, providing tourists with quiet spaces for doing yoga.
Ayurvedic massage is unique in many wellness retreats in India, bringing relaxing and soothing experiences for tourists. This massage therapy uses oils, herbs, and natural products to help tourists relieve emotional stress, rejuvenate their mind and soul.
“To experience wellness tours in India, travelers just need to prepare a valid passport to apply for an Indian visa, ” said Mrs. Kim, Relationship Manager in Indian Immigration Services.
Useful tips for tourists from Indian Immigration Service Experts
For a pleasant trip to India, travelers should get a visa beforehand. “To choose a reliable partner for making an eVisa, travelers need to consider factors including the fees, processing time, and professionalism of the staff,” Mrs. Kim also said.
Instead of visiting the embassy to apply for a India visa, foreign travelers can obtain an eVisa on the Indian Immigration Services website. As an applicant, travelers need to meet the visa requirements to be granted an Indian eVisa for tourists.
India Immigration Services makes it easier for travelers to apply for an Indian visa online with reasonable Indian eVisa fees. We assisted more than 25,000 customers globally in making eVisas to India. In addition, we also offer Travel Insurance in order to help our customers cover the cost of medical treatments during the trip.
No more complicated process to get a Visa to enter India, travelers now can expect to have a memorable wellness trip in this fascinating country with India Immigration Services.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220608005070/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom